Acta Neuropathologica

, Volume 128, Issue 1, pp 151–153 | Cite as

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors

  • Kim S. Bull
  • Colin R. Kennedy
  • Simon Bailey
  • David W. Ellison
  • Steven C. CliffordEmail author

Reduced health-related quality of life (HRQoL), including impaired cognitive, social, physical, behavioural and emotional functioning, is common in children treated for medulloblastoma [1, 2, 7] and has been associated with clinical factors such as surgical resection and treatment modality [2, 5, 6]. Recent biological advances have allowed the distinction of medulloblastomas into four consensus molecular subgroups—WNT, SHH, Group 3 and Group 4—which display distinct molecular, clinical, and pathological disease characteristics [3, 4, 8, 9]. Together, these observations raise the hypothesis that HRQoL in medulloblastoma survivors may be related to their underlying tumour biology.

We have previously reported the extensive characterisation of clinical outcomes [10], HRQoL [2], and biomarker-driven prognostication schemes [4] for children with medulloblastoma treated on the SIOP-UKCCSG PNET3 clinical trial. Moreover, we have recently described, in this journal, the robust assignment of...


Medulloblastoma Craniospinal Irradiation HRQoL Outcome Molecular Subgroup Total Difficulty Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was conducted on behalf of the UK Children’s Cancer and Leukemia Group (CCLG), and was supported by Grants from The Brain Tumour Charity and Cancer Research UK. Medulloblastomas investigated in this study were provided as part of CCLG approved biological study BS-2007-04. This study was conducted with ethics committee approval from Newcastle/North Tyneside and Trent RECs (study reference numbers 07/Q0905/71; MREC/02/4/019). The task of identifying associations between biological subtype and quality of survival was made possible by funding from the European Union’s Seventh Framework Programme (FP7/2007-13) under the project ENCCA, grant agreement HEALTH-F2-2011-261474.

Supplementary material

401_2014_1300_MOESM1_ESM.docx (22 kb)
Supplementary material 1 (DOCX 22 kb)
401_2014_1300_MOESM2_ESM.docx (22 kb)
Supplementary material 2 (DOCX 22 kb)


  1. 1.
    Bhat SR, Goodwin TL, Burwinkle TM et al (2005) Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol 23:5493–5500PubMedCrossRefGoogle Scholar
  2. 2.
    Bull KS, Spoudeas HA, Yadegarfar G et al (2007) Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors—On behalf of the CCLG (formerly UKCCSG). J Clin Oncol 25:4239–4245PubMedCrossRefGoogle Scholar
  3. 3.
    Ellison DW, Dalton J, Kocak M et al (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381–396PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Ellison DW, Kocak M, Dalton J et al (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400–1407PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Kennedy C, Bull K, Chevignard M et al (2014) Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. Int J Radiat Oncol Biol Phys 88:292–300PubMedCrossRefGoogle Scholar
  6. 6.
    Konczak J, Schoch B, Dimitrova A et al (2005) Functional recovery of children and adolescents after cerebellar tumour resection. Brain 128:1428–1441PubMedCrossRefGoogle Scholar
  7. 7.
    Palmer SL, Armstrong C, Onar-Thomas A et al (2013) Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol 31:3494–3500PubMedCrossRefGoogle Scholar
  8. 8.
    Schwalbe EC, Williamson D, Lindsey JC et al (2013) DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 125:359–371PubMedCrossRefGoogle Scholar
  9. 9.
    Taylor MD, Northcott PA, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465–472PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Taylor RE, Bailey CC, Robinson K et al (2003) Results of a randomized study of pre-radiation chemotherapy versus radiotherapy alone for non-metastatic medulloblastoma: the International Society of Paediatric Oncology United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21:1581–1591PubMedCrossRefGoogle Scholar
  11. 11.
    Wefers AK, Warmuth-Metz M, Pöschl J et al (2014) Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathol 127:931–933PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Kim S. Bull
    • 1
  • Colin R. Kennedy
    • 1
    • 2
  • Simon Bailey
    • 3
  • David W. Ellison
    • 4
  • Steven C. Clifford
    • 3
    Email author
  1. 1.Faculty of MedicineUniversity of Southampton, Southampton General HospitalSouthamptonUK
  2. 2.University Hospital Southampton NHS Foundation TrustSouthamptonUK
  3. 3.Northern Institute for Cancer ResearchNewcastle University, Sir James Spence Institute Level 5, Royal Victoria InfirmaryNewcastle upon TyneUK
  4. 4.Department of PathologySt. Jude Children’s Research HospitalMemphisUSA

Personalised recommendations